An organisational design approach of business environments: the case of Barcamps milieu in Paris

International audienceShifting business environment is often described as a decisive factor for organisational transformations. Various levels of organisation are proposed by the literature in order for an enterprise to be able to handle factors that outreach their boundaries. In this paper, we examine the case of Barcamps, a novel organisational pattern addressing issues beyond productivity and efficiency. We propose an analysis of its design parameters and functional requirements, contributing to the research and practice of organisational design beyond the boundaries of a specific organisation

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Background and purpose: Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods: In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3 years. The comparative analyses for (1) dabigatran vs rivaroxaban or apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results: The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0 years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions: Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Registration: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013

Anticoagulant selection in relation to the SAMe-TT2R2 score in patients with atrial fibrillation. the GLORIA-AF registry

Aim: The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during anticoagulation with vitamin K antagonists (VKA) and those with scores >2 might be better managed with a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may be prescribed less frequently to patients with AF and SAMe-TT2R2 scores >2 than to patients with lower scores. Methods and results: We analyzed the Phase III dataset of the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF), a large, global, prospective global registry of patients with newly diagnosed AF and ≥1 stroke risk factor. We compared baseline clinical characteristics and antithrombotic prescriptions to determine the probability of the VKA prescription among anticoagulated patients with the baseline SAMe-TT2R2 score >2 and ≤ 2. Among 17,465 anticoagulated patients with AF, 4,828 (27.6%) patients were prescribed VKA and 12,637 (72.4%) patients an NOAC: 11,884 (68.0%) patients had SAMe-TT2R2 scores 0-2 and 5,581 (32.0%) patients had scores >2. The proportion of patients prescribed VKA was 28.0% among patients with SAMe-TT2R2 scores >2 and 27.5% in those with scores ≤2. Conclusions: The lack of a clear association between the SAMe-TT2R2 score and anticoagulant selection may be attributed to the relative efficacy and safety profiles between NOACs and VKAs as well as to the absence of trial evidence that an SAMe-TT2R2-guided strategy for the selection of the type of anticoagulation in NVAF patients has an impact on clinical outcomes of efficacy and safety. The latter hypothesis is currently being tested in a randomized controlled trial. Clinical trial registration: URL: https://www.clinicaltrials.gov//Unique identifier: NCT01937377, NCT01468701, and NCT01671007

Collective intimacy and the organisation of distributed innovation

International audienc

Quand les utilisateurs créent l'industrie : le cas des applications Web

The current study explores the curiously not much studied in management problem of innovation of contemporary Web-based applications. Starting from the distinction between user (U) and manufacturer/entrepreneur (E) innovation and using a phenomenon-based research approach, it identifies a third actor, the developer (D), whose action is found to lie in-between the two. Three actor figures are proposed for his description: user-developer (UD), user-developer-entrepreneur (UDE) and developer- entrepreneur (DE).This interpretative framework (U, D, E) is tested in the second part on the cases of three industries, where it enables a tracing of their history, from their birth to their maturity: radio industry, PC industry and enterprise computer industry. The important role of D actor is identified in all three settings. Their development phases can be read as a sequence of innovations related to different actors, UDs, UDEs and DEs successively, until the proposition of a rationalisation by enterprises (Es) and leading to the independence of the three actors, U, D, E.During the intermediate maturity phase of the Web, where expert enterprises Es have appeared, yet the de- velopers Ds remain under the forms of DEs or UDEs, the question posed for enterprises is how to harness their activity for innovation. Three management modes are identified in the third part. The first method consists in fostering the self-revelation of these actors. The second consists in harnessing their action using ephemeral settings for the exploration of the potential of a given service. The last consists in animating a community of developers already using the enterprise's technology to encourage them in developing applications on the basis of this technology.La présente étude explore le problème, curieusement peu étudié en gestion, de l'innovation dans le développement des applications Web. En partant de la distinction entre innovation par " l'usager " (U) et innovation par " l'industriel/entrepreneur " (E) et en utilisant une approche de " phenomenon-based research ", elle identifie un troisième acteur, le " développeur " (D), dont l'action se positionne entre les deux autres. Trois figures d'acteur sont proposées pour le décrire : celle de l'usager-développeur (UD), de l'usager-développeur-entrepreneur (UDE) et du développeur-entrepreneur (DE).Cette grille de lecture (U, D, E) est testée, dans la 2ème Partie, sur le cas de trois industries dont on peut retracer l'histoire, depuis leur genèse jusqu'à des stades de maturité avancés : l'industrie des radiocommuni- cations, celle du PC, celle de l'ordinateur d'entreprise. L'importance du rôle joué par l'acteur D identifié se retrouve dans chacune de ces 3 industries. Les étapes de développement de chacune de ces industries peuvent être lues comme une suite d'innovations liées à des acteurs différents - successivement : UDs, UDEs, DEs - jusqu'à l'étape de proposition de rationalisations par des entreprises (Es) puis d'autonomisation de chacun trois acteurs U, D, E.Dans la phase de maturité intermédiaire que connaît le Web où sont déjà apparues des entreprises spéciali- sées E mais où les développeurs D continuent à exister sous les formes riches de DEs ou d'UDEs, se pose la question pour les entreprises de savoir comment mobiliser et gérer l'activité de ces développeurs à des fins d'innovation. Trois formes de gestion sont identifiées dans la 3ème Partie. La première méthode consiste à favoriser l'auto-révélation de ces acteurs. La seconde consiste à mobiliser ces acteurs dans des actions éphé- mères visant l'exploration du potentiel d'un service donné. La dernière consiste à animer une communauté de développeurs qui utilisent déjà la technologie de l'entreprise pour les encourager à développer des applications sur la base de cette technologie.Mots clés : développement des applications Web, innovation par les usagers, innovation par les industriels, entrepreneurs, développement industriel, potentiel technologique

(Re)designing the Internet: The limits of network approaches

International audienc

Au-delà des institutions : l’« intimité collective » à l’origine de l’émergence industrielle

International audienc